Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Chen, J; Röcken, C; Nitsche, B; Hosius, C; Gschaidmeier, H; Kahl, S; Malfertheiner, P; Ebert, MP 
Titel:
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. 
Abstract:
Imatinib targets KIT and platelet-derived growth factor receptors (PDGFR) and is highly effective in the treatment of CML and GIST patients. Pancreatic cancers express KIT and PDGFRs. Therefore, 26 patients with unresectable pancreatic cancer were randomized to either gemcitabine (1000 mg/m2 weekly) or imatinib (2x400 mg po) treatment daily. Pancreatic adenocarcinoma was confirmed histologically and expression of KIT and PDGFRbeta was determined immunohistochemically in the biopsy specimens. Qua...    »
 
Zeitschriftentitel:
Cancer Lett 
Jahr:
2006 
Band / Volume:
233 
Heft / Issue:
Seitenangaben Beitrag:
328-37 
Sprache:
eng 
Print-ISSN:
0304-3835 
TUM Einrichtung:
II. Medizinische Klinik und Poliklinik